Webcasts
Expert's Viewpoint
- Webinar Snippet: What Are The Current Roles Of Mexiletine In The Management Of VT?
- Webinar Snippet: Case Presentation: Ventricular Tachycardia Storm Associated With Myocardial Infarction
- Webinar Snippet: How Does Mexiletine Act As An Antiarrhythmic Drug?
- Webinar Snippet: How is the Usage of Mexiletine in Indian Practice?
- Webinar Snippet: What is the Role of Mexiletine in Combination with Beta Blockers?
- Webinar Snippet: What are the Electrophysiologic Properties of Mexiletine, a Class Ib AAD?
- Webinar Snippet: Role of amiodarone in management of VAs
- Webinar Snippet: Diagnosis of Different Types of Ventricular Arrythmias
- Webinar Snippet: Evaluation of a Patient with Ventricular Tachycardia
- Webinar Snippet: Case Presentation: Rescue Act by Mexiletine in VT/VF Storm Post PCI
- Webinar Snippet: Role of Mexiletine as Anti-Arrhythmic Agent
- Webinar Snippet: Is ‘Mexiletine’ First Drug of Choice in the Management of VT?
- Webinar Snippet: What is the Recommended Dosage of Mexiletine?
Our Publications
Key Trials
Clinical Tools
Guidelines
- ESC: Management of Atrial Fibrillation (2020)
- ESC/AEPC: Management of Supraventricular Tachycardia (2019)
- AHA/ACC/HRS: Management of Patients with Atrial Fibrillation-A Focused Update (2019)
- AHA/ACC/HRS: Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2017)
- ACC: Periprocedural Management of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation - Expert Consensus (2017)
- AHA: Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death (2016)
- ACC/AHA/HRS: Management of Supraventricular Tachycardia in Adult Patients (2015)
- ESC: Ventricular Arrhythmias and Prevention of Sudden Cardiac Death (2015)
- NICE: Management of Atrial Fibrillation (2014)
- AHA/ACC/HRS: Management of Atrial Fibrillation (2014)
- ESC: Cardiac Pacing and Cardiac Resynchronization Therapy (2013)
- ACCP: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed (2012)
Webcasts
Our Publications
- The Changing Landscape of CV Risk Reduction - Is LDL Lowering Sufficient: Questions & Answers (Dr. Michael Miller, USA)
- Newer Perspectives in Lipid Management: Questions & Answers (Dr. Harold Bays, USA)
- Newer Perspectives in Statin Therapy: Questions & Answers (Dr. Michael Davidson, USA)
- Atherogenic Dyslipidemia: Questions and Answers (Dr Abhimanyu Garg, USA)
- Dyslipidemia (Essence Series)
Our Research
Key Trials
- Coadministration of Telmisartan/amlodipine and Rosuvastatin Safe and Effective in Hypertensive Patients with Dyslipidemia
- HOPE-3: Lowering BP and LDL-Cholesterol Lowers the Risk of CV Events in Individuals without CVD
- HOPE 3: Long-term Cholesterol Lowering with Low-dose Rosuvastatin Alleviates CV Risk in Intermediate-Risk Multi-Ethnic Population
- ACCORD Eye: Impact of Intensive Treatment Strategies on Progression of Retinopathy in Type-2 Diabetes Mellitus Patients
- ACCORDION: Eye Benefits due to Intensive Glycemic Control Persist even 4 Years after Treatment Discontinuation
- IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Study
- SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels)
- TNT (Treating to New Targets) Trial
- CARDS Study (Collaborative Atorvastatin Diabetes Study)
- CLARIDI Study (Cholesterol Lowering and Arrhythmia Recurrences after Internal Defibrillator Implantation)
- CAPISH (Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy)
- ALLIANCE (Analysis of Aggressive Lipid-Lowering Initiation Abates New Cardiac Events)
- ROMA (Reduce the Incidence of MyocArdial Periprocedural Necrosis)
Clinical Tools
- Importance of Food Choices to Lower Low-Density Lipoprotein Cholesterol and Improve the Overall Lipoprotein Profile
- Impact of Specific Lifestyle Changes on Lipid Levels
- Role of Lipid Analyses for CV Disease Risk Estimation-ESC 2019-Lipid Guidelines
- Intervention Strategies as A Function of Total CV Risk and Untreated LDL Levels: ESC 2019 Lipid Guidelines
- Cardiovascular Risk Categories: ESC 2019 Lipid Guidelines
.jpg)
Guidelines
- ECS/EAS: Management of Dyslipidemias - Lipid Modification to Reduce CV Risk (2019)
- Heart UK: Management of Children and Young People with Heterozygous Familial Hypercholesterolemia (2019)
- ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA: Management of Blood Cholesterol (2018)
- ACC: Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk-Expert Consensus: Focused Update (2017)
- USPSTF: Use of Statins for the Primary Prevention of Cardiovascular Disease (2016)
- AHA: Management of Clinically Significant Drug Interactions with Statins and Select Agents Used in CVD (2016)
- ESC: Management of Dyslipidemia (2016)
- NICE: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease- An Update (2016)
- ACC: Role of Non-Statin Therapy for Lowering LDL-Cholesterol in the Management of Atherosclerotic Cardiovascular Risk-Expert Consensus (2016)
- KDIGO: Lipid Management in Chronic Kidney Disease (2013)
- ACC/AHA: Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013)
- NIH: Detection, Evaluation, and Treatment of High Blood Cholesterol – ATP III (2004)
- NFK KDOQI: Managing Dyslipidemias in Chronic Kidney Disease (2003)
Expert's Viewpoint
- Case Discussion on Acute MI with Fatigue and Dyspnoea
- Case Discussion on HTN with Discomfort, Fatigue Diagnosed as HFpEF
- Case Discussion on Chronic HFrEF and Acute Decompensation
- Importance of MRA in HF
- HF Cascade and Role Of MRA
- Initiate MRA Early in HF Patients
- Spironolactone in HFpEF
- Role of Eplerenone in HF
- The Real Benefit of MRA- Reduction in SCD
- When to Start MRA; Earlier the Better
- Benefit of MRA Depending on Phenotype
- MRA Benefit Beyond Neurohormones In Heart Failure
- MRA Benefit Beyond Diuresis
- Global Trends in Heart Failure – Issue 5 Q9
- Global Trends in Heart Failure – Issue 5 Q8
- Global Trends in Heart Failure – Issue 5 Q7
- Global Trends in Heart Failure – Issue 5 Q5
- Global Trends in Heart Failure – Issue 5 Q4
- Global Trends in Heart Failure – Issue 5 Q3
- Global Trends in Heart Failure – Issue 5 Q2
- Global Trends in Heart Failure – Issue 5 Q1
- Global trends in Heart Failure – Issue 4: Q5
- Global trends in Heart Failure – Issue 4: Q4
- Global trends in Heart Failure – Issue 4: Q6
- Global trends in Heart Failure – Issue 4: Q3
- Global trends in Heart Failure – Issue 4: Q2
- Global trends in Heart Failure – Issue 4: Q1
- Global trends in Heart Failure – Issue 3: Q3
- Global trends in Heart Failure – Issue 3: Q2
- Global trends in Heart Failure – Issue 3: Q1
- Global Trends in Heart Failure – Issue 2: Q9
- Global Trends in Heart Failure – Issue 2: Q8
- Global Trends in Heart Failure – Issue 2: Q7
- Global Trends in Heart Failure – Issue 2: Q6
- Global Trends in Heart Failure – Issue 2: Q5
- Global Trends in Heart Failure – Issue 2: Q4
- Global Trends in Heart Failure – Issue 2: Q3
- Global Trends in Heart Failure – Issue 2: Q2
- Global Trends in Heart Failure – Issue 2: Q1
- Global Trends in Heart Failure – Issue 1: Q7
- Global Trends in Heart Failure – Issue 1: Q6
- Global Trends in Heart Failure – Issue 1: Q5
- Global Trends in Heart Failure – Issue 1: Q4
- Global Trends in Heart Failure – Issue 1: Q3
- Global Trends in Heart Failure – Issue 1: Q2
- Global Trends in Heart Failure – Issue 1: Q1
Our Publications
Key Trials
- Meta-analysis on the Efficacy and Safety of Sacubitril/valsartan in Heart Failure
- TRANSITION: Impact of Sacubitril/valsartan on NT-proBNP in Hospitalized HFrEF Patients
- Role of Echocardiographic Biomarkers to Ascertain the Effect of Sacubitril–valsartan on Vascular Properties in Patients with HFrEF
- Impact of Sacubitril/Valsartan on Renal Outcomes in HFpEF Patients
- Insights from PARAGON-HF: Sacubitril/Valsartan Favorably Alter the Biomarkers of Extracellular Matrix Regulation in HFpEF Patients
- TRANSITION Study: Feasible and Safe to Initiate Sacubitril/Valsartan Pre-discharge in Acute HFrEF
- Impact of Sacubitril-Valsartan Treatment on Patients Hospitalized for Acute Decompensated HF
- Sacubitril/Valsartan Improves Physical and Social Activity Limitations in HFrEF Patients
- Sacubitril/Valsartan vs. Enalapril in HFrEF Patients: Analyzing the Renal Impact and Associated Outcomes
- Initiation/Uptitration of Sacubitril/Valsartan in HFrEF Patients: Insights from the TITRATION Trial
- Efficacy and Safety of Sacubitril/Valsartan in HFrEF Patients with Low SBP: Insights from PARADIGM-HF
- Sacubitril/Valsartan in HFrEF Patients: Assessing the Benefits-Harms Balance
- Sacubitril/Valsartan Enhances Glycemic Control in Heart Failure Patients with Diabetes
- Sacubitril/Valsartan Treatment Cuts Down the 30-Day Readmission Rate vs. Enalapril after Heart Failure Hospitalization
- Angiotensin–Neprilysin Inhibition Superior to Enalapril in Heart Failure Patients with Reduced Ejection Fraction
- MERIT - HF Subanalysis in CHF Patients with Renal Dysfunction
Guidelines
- AHA/HFSA: Management of HF in Type-2 Diabetes Mellitus Patients (2019)
- ACC/AHA/HFSA: Management of Heart Failure-Focused Update of the 2013 Guidelines (2017)
- AHA: Role of Biomarkers for Prevention, Assessment, and Management of Heart Failure (2017)
- AHA: Scientific Statement on Drugs that May Cause or Exacerbate Heart Failure (2016)
- ACC/AHA/HFSA: Focused Update on New Pharmacological Therapy for Heart Failure (2016)
- ESC: Management of Acute and Chronic Heart Failure (2016)
- ESC: Diagnosis and Management of Hypertrophic Cardiomyopathy (2014)
- ACCF/AHA: Management of Heart Failure (2013)
- AHA: Decision Making in Advanced Heart Failure - A Scientific Statement (2012)
- ACCF/AHA: Diagnosis and Treatment of Hypertrophic Cardiomyopathy (2011)
- NICE: Management of Chronic Heart Failure in Primary and Secondary Care (2010)
Webcasts
- Current Trends in Hypertension Management
- Novel and Emerging Treatments for Hypertension
- Highlights of American Society of Hypertension Annual Scientific Meeting, 2015
- Hypertension Update 2014:Focus on New Guidelines
- Insights into JNC 2013 Guidelines, ASH and more...
- Hypertension: Challenges, Dilemmas and New Paradigms
- Recent Trends in Hypertension Management
Expert's Viewpoint
- Webinar Snippet: Treatment Preference: Line Of Treatment For Stage 2 & 3 HTN
- Webinar Snippet: Undesirable Combinations In HTN Management
- Webinar Snippet: Combination Therapy In HTN: Rationale And Benefits
- Webinar Snippet: Pharmacotherapy: First Line Drugs For HTN Management
- Webinar Snippet: Goal Of HTN Management
- Webinar Snippet: BP Threshold In CAD: BP Threshold And Target Goal In CAD Patient
- Webinar Snippet: CV Risk Assessment: Available Tools For CV Risk Assessment.
- Webinar Snippet: CV Risk Factors: Factors Influencing CV Disease, Mortality And Morbidity
- Evaluation Of HTN- What Should Be The Objective Behind Evaluation Of HTN?
- Webinar Snippet: ABPM: Important Points About ABPM
- Webinar Snippet: Out Of Office BP: Rationale Behind Out Of Office Blood Pressure Monitoring
- Webinar Snippet: BP Cut Off Values: BP Cut Off Values By Different Guidelines
- Webinar Snippet: Diagnosis Of HTN: Available Methods For Diagnosis Of HTN
- Webinar Snippet: Screening Of HTN: Key Precautions To Be Taken In BP Measurement
- Webinar Snippet: Epidemiology: Prevalence Of Uncontrolled Hypertension
Our Publications
Our Research
Key Trials
- Coadministration of Telmisartan/amlodipine and Rosuvastatin Safe and Effective in Hypertensive Patients with Dyslipidemia
- OPTIMISE Trial: Impact of Antihypertensive Medication Reduction in Elderly Hypertensive Patients
- Azilsartan is Superior to Olmesartan in Hypertensives with Type 2 Diabetes/ Prediabetes
- Azilsartan is More Effective than Olmesartan in Reducing BP in Hypertensive Patients
- HOPE-3: Lowering BP and LDL-Cholesterol Lowers the Risk of CV Events in Individuals without CVD
- SPRINT: Intensive BP lowering Superior in Terms of Lowering CV Events & Death vs. Standard BP lowering in High-Risk Patients without Diabetes
- PRISMA-I (Prospective, Randomised Investigation of the Safety and Efficacy of Telmisartan Versus Ramipril Using Ambulatory Blood Pressure Monitoring)
- ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global End-point Trial)
- ESPRIT (Efficacy & Safety in Patients with Renal Impairment treated with Telmisartan)
- ROADMAP (Randomized Olmesartan and Diabetes Microalbuminuria Prevention) Study
- PRISMA-II (Prospective, Randomised Investigation of the Safety and Efficacy of Telmisartan Versus Ramipril Using Ambulatory Blood Pressure Monitoring)
- SMOOTH (Study of Micardis in Overweight/Obese patients with Type-2 diabetes and Hypertension)
Patient Education
Guidelines
- ISH: Global Guideline on Hypertension (2020): How to Measure Blood Pressure Correctly?
- ISH: Global Guideline on Hypertension (2020): Lifestyle Modifications for the Management of Hypertension
- ISH: Management of Hypertension in Adults (2020)
- ISH: Optimal Recommendations for Hypertension (2020)
- ISH: Essential Recommendations for Hypertension (2020)
- NICE: Diagnosis and Management of Hypertension in Pregnancy (2019)
- NICE: Diagnosis and Management of Hypertension (2019)
- ADA: Management of Hypertension in Diabetes-An Update (2018)
- ESH/ESC: Management of Arterial Hypertension (2018)
- ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA: Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017)
- ADA: Diabetes and Hypertension - Position Statement (2017)
- ACP/AAFP: Pharmacological Management of Hypertension in Elderly (>60 years) (2017)
- AHA: Impact of Hypertension on Cognitive Function (2016)
- ASH/ISH: Clinical Practice Guidelines for the Management of Hypertension in the Community (2014)
- Panel of JNC 8: Management of High Blood Pressure (2014)
- AHA: Ambulatory Blood Pressure Monitoring in Children and Adolescents – A Scientific Statement (2014)
- API: Indian Guidelines on Hypertension – III (2013)
- ACCF/AHA: Hypertension in the Elderly - Expert Consensus (2011)
- NICE: Clinical Management of Primary Hypertension (2011)
- NFK KDOQI: Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)
Webcasts
Expert's Viewpoint
- Webinar Snippet: Indian Scenario of Patients with STEMI during COVID-19 Pandemic: Poll Results
- Webinar Snippet: ESC Guidance for General Precautions for Clinicians in The Cath Labs During COVID-19 Pandemic
- Webinar Snippet: ESC Guidance on The Clinical Importance of High-Sensitivity Troponin Test in This Pandemic Time?
- Webinar Snippet: In the Recent Pandemic, What Are the Factors That Affect Timely Reperfusion Therapy in Patients With STEMI?
- Webinar Snippet: ESC Guidance on The Protocol for Triage/Testing of STEMI Patients in The Current Times
- Webinar Snippet: Use Of Anticoagulants In Patients With STEMI Treated With Fibrinolytics
- Webinar Snippet: Role Of Reteplase In STEMI
- Webinar Snippet: Dosing And Administration Of Reteplase In Patients With STEMI
- Webinar Snippet: Comparison Between Fibrinolytic Agents In STEMI
- Webinar Snippet: In Management Of Patients With STEMI, Is Pharmaco-Invasive Approach Equivalent To Primary PCI In Terms Of Outcomes?
- Webinar Snippet: What Are The Barriers To Gold Standard Treatment And How Can These Be Alleviated For Indian Patients With STEMI?
- Webinar Snippet: What Is The Most Important Factor In The Management Of STEMI?
- Webinar Snippet: Indian Scenario Of Patients With STEMI During COVID-19 Pandemic: Poll Results
- Webinar Snippet: ESC Guidance On The Clinical Importance Of High-Sensitivity Troponin Test In This Pandemic Time?
- Webinar Snippet: ESC Guidance For General Precautions For Clinicians In The Cath Labs During COVID-19 Pandemic
- Webinar Snippet: ESC Guidance On The Protocol For Triage/Testing Of STEMI Patients In The Current Times
- Webinar Snippet: In The Recent Pandemic, What Are The Factors That Affect Timely Reperfusion Therapy In Patients With STEMI?
- The Need to Move to New Generation Lytics
- Thrombolytics in the Era of Intervention
Our Publications
Key Trials
- Prolonged DAPT Favorably Impacts the Risk-Benefit Ratio in ‘TWILIGHT’-like High-Risk Patients after Complex PCI
- ISCHEMIA: Early Invasive vs. Conservative Strategy for Patients with Stable CAD
- The FAST-MI Programme: A Comparison of Five-year Outcomes in STEMI Patients Treated with Early pPCI, Late pPCI or Pharmacoinvasive Strategy
- Prasugrel Renders Superior Efficacy vs. Ticagrelor in ACS Patients Undergoing Invasive Evaluation
- SMART-DATE Trial: Long-Term DAPT-The Standard of Care for ACS Patients Undergoing PCI with DES
- VERDICT Trial: A Head-to-Head Comparison of Early vs. Standard Care Invasive Strategy in NTSE-ACS Patients
- Six Months vs. Twelve Months of DAPT in Event-Free STEMI Patients after Primary PCI with Second Generation DES
- Prasugrel is Superior or Equivalent to Ticagrelor in ACS Patients undergoing PCI: A Systematic Review and Meta-Analysis
- PRAGUE-18: Prasugrel & Ticagrelor - Similar Efficacy in AMI Patients Undergoing Primary PCI
- STEPP-AMI Two-Year Follow-up: Pharmacoinvasive Strategy vs. Primary PCI in Indian STEMI Patients
- STEPP-AMI: Pharmacoinvasive Strategy vs. Primary PCI in Indian Patients with STEMI
- ATOLL (Angioplasty and Intravenous Lovenox or Unfractionated Heparin)
- CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events)
- TNT (Treating to New Targets) Trial
- PCI-CURE (Percutaneous Coronary Intervention's Clopidogrel in Unstable Angina to Prevent Recurrent Events)
- CLARIDI Study (Cholesterol Lowering and Arrhythmia Recurrences after Internal Defibrillator Implantation)
- ROMA (Reduce the Incidence of MyocArdial Periprocedural Necrosis)
- ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global End-point Trial)
- ALLIANCE (Analysis of Aggressive Lipid-Lowering Initiation Abates New Cardiac Events)
- CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy- Thrombolysis In Myocardial Infarction 28)
- CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events)
- IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Study
Patient Education
Clinical Tools
Guidelines
- ESC: Management of Acute Coronary Syndrome in Patients presenting without ST-segment Elevation (2020)
- ESC: Diagnosis and Management of Chronic Coronary Syndrome (2019)
- ESC: Myocardial Revascularization (2018)
- ESC/ACCF/AHA/WHF Task Force: Third Universal Definition of Myocardial Infarction (2018)
- ESC/EACTS: DAPT in Coronary Heart Disease-A Focused Update (2017)
- ESC: Management of ST-Elevation Myocardial Infarction (2017)
- AHA: Meal Timing and Frequency for Prevention of Cardiovascular Diseases-A Scientific Statement (2017)
- USPSTF: Use of Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancers (2016)
- ACC/AHA: Focused Update on DAPT Duration in Patients with Coronary Artery Disease (2016)
- AHA: Management of Acute Myocardial Infarction in Women (2016)
- AHA: Secondary Prevention After Coronary Artery Bypass Graft Surgery (2015)
- ACC/AHA/SCAI: Percutaneous Coronary Intervention (PCI) for ST-Elevation Myocardial Infarction (STEMI)- Focused Update of 2011 Guidelines for PCI and 2013 Guidelines for the Management of STEMI (2015)
- ACC/AHA/AATS/PCNA/SCAI/STS: Diagnosis and Management of Patients with Stable Ischemic Heart Disease – Focused Update of 2012 Guidelines (2014)
- AHA/ACC: Management of Non-ST-Elevation Acute Coronary Syndrome (2014)
- AHA: Depression as a Risk Factor for Poor Prognosis among Patients with Acute Coronary Syndrome – A Scientific Statement (2014)
- SCAI/ACC/AHA: Percutaneous Coronary Intervention without On-Site Surgical Backup - Expert Consensus (2014)
- ACCF/AHA: Management of ST-Elevation Myocardial Infarction (2013)
- NICE: Early Management of Unstable Angina/Non-ST-Elevation Myocardial Infarction-An Update (2013)
- ACCF/AHA: Management of Patients with Unstable Angina/Non–ST-Elevation Myocardial Infarction - Focused Update of 2007 Guidelines (2012)
- ACCP: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed (2012)
- ACCF/AHA/SCAI: Percutaneous Coronary Intervention (2011)
- AHA: Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac Disease – Scientific Statement (2011)
- NICE: Hyperglycemia in Acute Coronary Syndrome (2011)
- ACC/AHA: Chronic Stable Angina - Focused Update of 2002 Guidelines (2007)
Webcasts
- New Trends in The Diagnosis and Management of Pulmonary Hypertension
- Medical Management of Chronic Thromboembolic Pulmonary Hypertension
- Aetiopathology and Prevention of CTEPH
- Caring of Patients: Beyond Medical Management
- Role of CT Pulmonary Angiogram and MRI in PAH
- Connective Tissue Associated Pulmonary Hypertension
- Interventions for PH: An Overview
- Aetiology and Pathobiology of PH due to Left Heart Diseases
- Understanding from Indian Registries
- Short Introduction to the Current Medications for Management of PH
- Screening and Diagnostic Strategies to Identify Early PAH - PH due to Rheumatological Disease
- Medical Management of PH due to Left Heart Disease
- Echocardiographic Evaluation of PAH: What is New?
- Exercise Testing and Conditioning in PH
- Cardiac Catheterization: Is it Necessary?
- Medical Management of PAH: How to Choose the Best Treatment?
- Risk Stratification and Medical Management of Pulmonary Hypertension
- Hemodynamic Definitions and Updated Classification of Pulmonary Hypertension [6th World Pulmonary Hypertension Symposium]
- PURVIEW - Pulmonary Hypertension
- The New Era in PAH
Key Trials
- Anticoagulation Management Post-PEA in Patients with CTEPH: The Current Scenario
- Risk Stratification in PAH with a Comprehensive Echocardiographic Method
- Long Term Treatment with Riociguat Sustains Clinical Benefits for upto One Year in CTPH
- Treatment with Macitentan Reduces Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension – SERAPHIN Study
